Gonadothropin-releasing hormone agonist as a treatment of choice for central precocious puberty

Jose R.L. Batubara



DOI: https://doi.org/10.13181/mji.v19i4.418

Abstract


Precocious puberty is defi ned as pubertal development which occurs too early. The age limit in this term is based on the onset of puberty in normal population. Some points have to be taken into account, such as ethnicity, gender, nutritional conditions, and secular trends. In girls, precocious puberty is defi ned by breast development occured before 8 years old. In boys, precocious puberty is defi ned as gonadarche or pubarche before 9 years of age. The clinical course of precocious puberty varies widely, ranging from alternating, slowly progressive, and rapidly progressive    form. The rapidly progressive forms of idiopathic central precocious puberty need to be treated because it may result in early epiphyseal closure and short fi nal height, and also pyschosocial problems in the affected children and the family. The aims of treatment are to arrest physical maturation, prevent early menarche, and also improve adult height combined with normal body proportions. Gonadotropin releasing hormone analogue is the treatment of choice for central precocious puberty. Gonadotropin releasing horomone analogue has suppressive effect on the pituitarygonadal axis, therefore it suppresses LH secretion. This leads to the return of estradiol and testosterone to prepubertal levels. Treatment using gonadotropin releasing horomone analogue is shown to reduce breast size, pubic hair, ovarian and uterine size in girls, and decrease testicular size in boys. Gonadotropin releasing hormone analogue is effective in halting progression of secondary sexual characteristics development, presenting menstrual cycle, slowing bone-age advancement, and also improving fi nal height. (Med J Indones 2010; 19:287-92)

Keywords: gonadache, GRH analogue, pubarche , precocious puberty


Full Text:

PDF

References


  1. Partsch CJ, Sippell WG. Pathogenesis and epidemiology
  2. of precocious puberty. Effects of exogenous oestrogens.
  3. Human Reproduction Update 2001;7(3):292-302
  4. Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J,
  5. Bourguignon JP. The timing of normal puberty and the age
  6. limits of sexual precocity: variations araound the world,
  7. secular trends, anda changes after migration. Endocrine
  8. Reviews 2003;24(5):668-93
  9. Teilmann G, Pedersen CB, Jensen TK, Skakkebek NE,
  10. Juul A. Prevalence and incidence of precocious pubertal
  11. development in Denmark: an epidemiologic study based on
  12. national registries. Pediatrics 2005;116(6):1323-8
  13. Hirsch HD, Gillis D, Strich D, Chertin B, Farkas A,
  14. Lindenberg T. The histrelin implant: a novel treatment for
  15. central precocious puberty. Pediatrics 2005;116; 798-802
  16. Heger S, Partsch CJ, Sippell WG. Long-term outcome after
  17. depot gonadotropin-releasing hormone agonist treatment of
  18. central precocious puberty: fi nal height, body proportions,
  19. body composition, bone mineral density, and reproductive
  20. function. J Clin Endocrinol Metab. 1999;4(12):4583-90
  21. Partsch CJ, Heger S, Sippell WG. Management and outcome
  22. of central precocious puberty. Clinical Endocrinology 2002;56(2):129-48
  23. Carel JC, Leger J. Precocious puberty. N Engl J Med
  24. ;358:2366-77
  25. Fahmy JL, Kaminsky CK, Kaufman F, Nelson MD, Parisi
  26. MT. The radiological approach to precocious puberty. Br J
  27. Radiol. 2000;73:560-7
  28. Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C,
  29. Brauner R. Central precocious puberty: clinical and laboratory
  30. features. Clinical Endocrinology. 2001;54:289–94
  31. Stanhope R, Traggiai C. Precocious puberty (complete,
  32. partial). Sultan C (ed): Pediatric and Adolescent Gynecology.
  33. Evidence-Based Clinical Practice. Endocr Dev. Basel,
  34. Karger, 2004, vol 7, pp 57–65
  35. Casper RF. Clinical uses of gonadotropin-releasing hormone
  36. analogues. Can Med Assoc J. 1991;144(2):153-8
  37. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM,
  38. Durham E, et al. Sequential comparisons of one-month and
  39. three-month depot leuprolide regimens in central precocious
  40. puberty. J Clin Endocrinol Metab. 2006;91(5):1862-7
  41. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier
  42. C, Colle M. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25mg). J Clin Endocrinol Metab. 2002;87(9):4111-6
  43. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB. Increased fi nal height in precocious puberty after long-term treatment with LHRH agonists: The National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86(10):4711–6
  44. Micillo M, Salerno M, Offi cioso A, et al. Near fi nal height
  45. after GnRH agonist treatment in central precocious puberty.
  46. J Pediatr Endocrinol Metab. 2000;13(Suppl 1):787–90
  47. Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5–8.5 years. Arch Dis Child. 1999; 81:329–32
  48. Bouvattier C, Coste J, Rodrigue D, et al. Lack of effect
  49. of GnRH agonists on fi nal height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab. 1999; 84:3575–8
  50. Diaz A, Danon M. Recent advances in the diagnosis and treatment of precocious puberty. Indian J Pediatr. 2000;67(3):211-5
  51. Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing
  52. the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol. 2000;163:838–44
  53. Kim HS. Clinical application of gonadotropin-releasing hormone analogs in children and adolescents. Korean J Pediatr. 2010;53(3):294-9
  54. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di
  55. Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing
  56. hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2007;93(1):190-5





Copyright (c) 2010 Jose R.L. Batubara

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles and issues in Medical Journal of Indonesia have unique DOI number registered in Crossref.
 
Romeo
 
 
http://mji.ui.ac.id/journal/index.php/mji/pages/view/stat
Unique Visitors